Guidelines for Clinical Research on Acupuncture
(1995; 68 pages)
Table of Contents
View the documentForeword
Open this folder and view contents1. Introduction
Open this folder and view contents2. Glossary
Open this folder and view contents3. Goals and objectives of the guidelines
Open this folder and view contents4. General considerations
Close this folder5. Research methodology
View the documentLiterature review
View the documentTerminology and technology
View the documentInvestigators
View the documentClinical research design and rational use of acupuncture
View the documentRandomized controlled clinical trial design
View the documentProtocol development
View the documentResearch knowledge
View the documentCase report forms
View the documentData management
View the documentEthics review board
View the documentStatistical analysis
View the documentMonitoring of studies
View the documentReporting
View the documentImplementation
View the documentConclusions
View the document6. Using the guidelines
Open this folder and view contentsAnnexes
View the documentBibliography
View the documentSelected WHO publications of related interest
View the documentBack cover

Ethics review board

The protocol should be considered by an ethics review board. The board will generally be established at an institutional level, but boards existing at a regional or national level can also be used. The board will be an independent body made up of both medical and non-medical members who are not involved in the experimental activity of evaluation under review. The board will verify that the rights of patients participating in the evaluation are protected and that the trial is justified in both medical and social terms. The board will also consider the suitability of the protocol as it relates to patient selection and patient protection, and the issues of informed consent for patients. However, this board should not promote methodological guidance unless it has appropriate expertise in acupuncture research. The work of the board should be guided by the Helsinki Declaration (see Appendix 2) and other related documents prepared by the individual country or institutions. If beneficial effects are demonstrated for the experimental group, patients allocated to the control group should be offered the possibility of receiving the experimental treatment.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017